Saturday, November 21st, 2009

Posts Tagged ‘ Pfizer ’

Biotech Stocks: The One Sector Outperforming The S&P 500

Mar 24th, 2009 | By Marc Lichtenfeld | Category: Stock Market Investing, Top Story

With so many biotech stocks making big moves and pharmaceutical merger activity moving faster than anything else right now, we turned to one of the smartest analysts in the lucrative biotech field to give us his take on what we should be doing…



How Stem Cells Create Mega Opportunities In Biotech Stocks

Nov 19th, 2008 | By Patrick Cox | Category: Featured

New breakthroughs in adult stem cell technology offer staggering implications for medical science, says Patrick Cox. And a massive opportunity for investors. As Big Pharma move in, Patrick says biotech companies involved in stem cell research and RNA technology could become the “investment of a lifetime.”



Don’t Be Suckered in by This Big Dividend

Jun 13th, 2008 | By Rob Fannon | Category: Stock Market Investing

It’s no secret I’m a Big Pharma bear. And my favorite target is Pfizer, the world’s largest drug company.



Do Yourself a Favor and Dump These Stocks Immediately

May 23rd, 2008 | By Rob Fannon | Category: International Investing

One of the drug industry’s biggest superstars right now is a cancer drug called Sutent.



Big Drug Stocks: Cheaper Than They’ve Ever Been

May 17th, 2008 | By Steve Sjuggerud | Category: Stock Market Investing

Pfizer – the biggest pharmaceutical company in the world – is the cheapest it’s ever been in recorded history.



Don’t Count on the Fed to Save Your Favorite Stocks in 2008

Apr 19th, 2008 | By Eric Roseman | Category: Stock Market Investing

The Dow and most foreign stock-markets enjoyed a blistering rally on Wednesday but heading into yesterday morning’s trade the futures look pretty ugly.



Last Chance to Get in on This No-Brainer Biotech Trade

Apr 11th, 2008 | By Dr. George Huang | Category: Stock Market Investing

Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”